DiaMedica Q3 Loss Widens to $11.3M; ReMEDy2 Hits 200-Patient Interim Analysis Threshold
DMAC sits 78% above its 52-week low of $5.245.
Summary
DiaMedica reported a wider Q3 net loss of $11.3M and $34.9M in cash, enough to fund operations into Q4 2027. ReMEDy2 reached the 200-participant threshold for its interim analysis, expected in Q1 2027.
Key Events · Earnings and Guidance · DMAC
-
Q3 Loss Widens on Clinical Spend
Net loss was $11.3M for Q3 2026 versus $8.6M a year earlier, and the nine-month net loss reached $31.5M versus $24.0M. R&D rose to $9.2M in the quarter from $6.4M, driven by ReMEDy2 expansion and preeclampsia trial start-up.
-
Cash Down to $34.9M, Runway Into Q4 2027
Cash, equivalents and short-term investments fell to $34.9M at September 30 from $59.9M at December 31, 2025, with $26.0M of operating cash burn over nine months. Management projects funding into Q4 2027.
-
ReMEDy2 Reaches Interim Analysis Threshold
Enrollment passed the prespecified 200 participants; the DSMB will run the interim analysis after the 200th patient completes 90-day follow-up, expected in Q1 2027. The outcome is either a sample-size re-estimation, a futility stop, or continuation toward a final size of 300 to 728 participants.
-
FGR Data Event Set for November 24
Enrollment is complete in the first two of three FGR cohorts (12 participants at 5 and 10 µg/kg). Preliminary interim topline results will be presented at a virtual KOL event on November 24, 2026.
Analysis · DMAC · Life Sciences
Cash burn is the real story this quarter: $34.9M remained at September 30 versus $59.9M at year-end, after $26.0M of net cash used in operations over nine months. Management says that funds operations into Q4 2027, covering the ReMEDy2 interim analysis expected in Q1 2027 — the binary event that determines whether the stroke program continues or stops for futility. With R&D climbing to $9.2M in the quarter from $6.4M a year ago as the trial expands globally and the preeclampsia program starts up, the runway has less slack than the headline suggests. Near term, preliminary FGR data at the November 24 KOL event offers the first look at the pregnancy franchise.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DMAC was trading at $9.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $503.1M. The 52-week trading range was $5.25 to $11.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.